Device or drug? Study answers questions about treating dangerous heart irregularities

April 09, 2000

DALLAS, April 11 -- A new rating scale may help doctors make better medical decisions about whether a person should receive a drug or a device to fix a potentially deadly heart irregularity, according to researchers reporting in today's Circulation: Journal of the American Heart Association.

Ventricular tachycardia (VT) is a rapid heartbeat that affects the lower chambers of the heart. Ventricular fibrillation (VF) is a quivering of the heart muscle. Both conditions reduce the heart's ability to pump blood and can result in collapse, cardiac arrest and sudden death, unless prompt medical attention is given.

Robert Sheldon, M.D., Ph.D., professor of medicine at the University of Calgary, Alberta, Canada, who headed the study, says that implantable defibrillators (ICDs) are better than medication for the oldest and sickest patients with VT or VF. Medication may be a better choice for those who are younger.

Implantable defibrillators are placed underneath the skin near the collarbone. They are programmed to react when a patient's "danger" level occurs and deliver an electric shock to the heart, speeding up the heart rate and stopping the arrhythmia.

The "gold standard" for drug treatment of VT/VF is amiodarone, says Sheldon. The medication changes the chemistry that creates electrical currents in the heart and prevents many recurrences of VT or VF. However, the drug can have serious side effects, including scarring of the lungs or liver, disruption of thyroid function and tremors. This is one reason why implantable defibrillators are being studied so intensely.

Compared to medication, ICDs reduced the death rate by half among individuals with VT or VF if they were 70 years or older, had poor left ventricular function (weaker contractions) and were bedridden or easily winded.

"These findings were quite unexpected," Sheldon says. "Not only do they suggest that older, sicker patients are most likely to benefit from receiving an ICD as first-line therapy, but they suggest that younger, healthier patients with VT/VF -- which include a larger segment of the population -- would have better treatment results with medication. If confirmed, these findings may have broad implications for the provision of therapy for patients with VT/VF."

Three large international studies found that implantable defibrillators reduced the death rate by 30 percent among VT/VF patients in general, compared to amiodarone. Patients with ICDs experienced improvement of quality of life provided they only need a few interventions from the device. Once patients needed shocks from their defibrillators, a sensation described by one of Sheldon's patients as "like being kicked by a mule," they may become dissatisfied with the devices.

In the latest study of 659 patients, the researchers again compared the two treatments with roughly half of the patients receiving the drug, and the other half receiving an implantable defibrillator. But this time, the subjects were divided into four groups based on risk factors such as being age 70 or older, having significantly decreased left ventricular function (ejection fraction), and having symptoms of heart failure such as a tendency to become short of breath while sitting or lying down.

The top quarter had the highest ratings on risk factors. This group that received an implantable defibrillator had 50 percent fewer deaths, compared to the high-risk group that received the medication. In those with at least two of the risk factors, the risk of dying in the year following treatment was about 14 percent in patients with the defibrillator and 30 percent in those receiving the drug.

Conversely, the youngest VT/VF patients with the least amount of left ventricular or functional impairment derived the least benefit from an implantable defibrillator compared to those who received the drug.

In an accompanying editorial, Arthur J. Moss, M.D., of the Heart Research Follow-Up Program at the University of Rochester Medical Center in Rochester, New York, wrote that because the sickest patients apparently benefit the most from defibrillators, the technique will become "increasingly targeted for patients with more severe heart disease."

Both Sheldon and Moss agree that further study is needed to confirm the findings.

Co-authors are Stuart Connolly, M.D.; Andrew Krahn, M.D.; Robin Roberts, M.Tech; Michael Gent, D.Sc. and Martin Gardner, M.D.
-end-
For more information about ventricular tachycardia or ventricular fibrillation, visit the American Heart Association's online Heart and Stroke A-Z Guide at http://www.americanheart.org.

American Heart Association

Related Medication Articles from Brightsurf:

New medication may treat underlying causes of hypertrophic cardiomyopathy
Mavacamten, a new investigational cardiac medication, may improve heart function for people with thickened heart muscle leading to obstructed blood flow through the heart, a condition known as obstructive hypertrophic cardiomyopathy.

Therapy plus medication better than medication alone in bipolar disorder
A review of 39 randomized clinical trials by scientists from UCLA and their colleagues from other institutions has found that combining the use medication with psychoeducational therapy is more effective at preventing a recurrence of illness in people with bipolar disorder than medication alone.

Kids diagnosed with ADHD often don't take medication regularly
Children diagnosed with ADHD inconsistently take their prescribed medication, going without treatment 40 per cent of the time, a new study has found.

Long-term medication for schizophrenia is safe
Researchers at Karolinska Institutet in Sweden and their colleagues in Germany, the USA and Finland have studied the safety of very long-term antipsychotic therapy for schizophrenia.

Which is more effective for treating PTSD: Medication, or psychotherapy?
A systematic review and meta-analysis led by Jeffrey Sonis, MD, MPH, of the University of North Carolina School of Medicine, finds there is insufficient evidence at present to answer that question.

ADHD medication: How much is too much for a hyperactive child?
When children with ADHD don't respond well to Methylphenidate (MPH, also known as Ritalin) doctors often increase the dose.

Pain medication use by children after common surgeries
About 400 caregivers reported pain medication use by children after common surgeries such as hernia, elbow fracture, appendectomy or adenoid removal in this study.

Bringing cancer medication safely to its destination
Treating cancer more selectively and more effectively -- this could be achieved with an innovative technology developed by teams of researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU).

Bullying linked to student's pain medication use
In a school-based survey study of all students in grades 6, 8, and 10 in Iceland, the use of pain medications was significantly higher among bullied students even when controlling for the amount of pain they felt, as well as age, gender, and socioeconomic status.

New medication gives mice bigger muscles
Researchers from Aarhus University, Denmark, have studied a new group of medicinal products which increase the muscle- and bone mass of mice over a few weeks.

Read More: Medication News and Medication Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.